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K. Scott Baker,3 Michael A. Pulsipher,5 Anna Petryk6The endocrine system is highly susceptible to damage by high-dose chemotherapy and/or irradiation before
hematopoietic cell transplantation (HCT) during childhood. The specific endocrine organs most affected by
HCT include the thyroid gland, the pituitary, and the gonads. In addition, hormones that support
development and stability of the skeletal system are also affected. Insufficiency of thyroid hormone is 1 of
the most common late sequelae of HCT, and occurs more often in young children. Deficiency in the
pituitary’s production of growth hormone is a problem of unique concern to the pediatric population.
The reproductive risks of HCT depend on the patient’s gender and pubertal status at the time of HCT.
Pubertal or gonadal failure frequently occurs, especially in females. Infertility risks for both genders remain
high, whereas methods of fertility preservation are limited in all but postpubertal males. Bone health post-
HCT can be compromised by low bone mineral density as well as avascular necrosis, but the data on both
problems in the pediatric HCT population are limited. In this paper, the current state of knowledge, gaps in
that knowledge, and recommendations for future research are addressed in detail for each of these systems.
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childhood [1]. The risks for the development of
endocrine dysfunction depend on a variety of factors,
including age at HCT, the type of conditioning
regimen utilized, and the gender of the patient. The
specific endocrine organs most affected by HCT
include the thyroid gland, the pituitary, gonads, and
hormones that support development and stability of
the skeletal system.
In April 2011, the National Cancer Institute/
National Heart, Lung and Blood Institute, along
with the Pediatric Blood andMarrowTransplant Con-
sortium sponsored a consensus conference of interna-
tional experts in clinical and biological research into
late effects after HCT convened to review the state
of the science of pediatric studies and identify key areas
for future research. This manuscript will describe the
conclusions shared at that conference relating to key
endocrine systems affected by HCT. Although there
is a large body of research evaluating endocrinologic
late effects after HCT in adults, the pediatric literature
is relatively limited. Children, especially those who are1725
Table 1. Studies of Thyroid Dysfunction (TD) Following Pediatric HCT*
Reference
Incidence
of TD Number Disease Conditioning F/U Median (range) Risk Factors
Michel et al., 1997 5 9% 26 AML BU + CY 5.9 years (1-9) None
Afify et al., 2000 6 0% 23 AML only BU + CY 4.9 years (2-10) None
Slatter et al., 2004 7 11% 83 PID only BU + CY NR (2-4.5) Autoimmunity?
Ishiguro et al., 2004 4 30% 147 Varied Varied 11.1 years (5.8-21.5) Age <10 years
Berger et al., 2005 8 27% 101 ALL only FTBI + Chemo 8.5 years (5-16.5) Age <10 years; Transplant in >CR1
29% 14 ALL only BU + Chemo
Leung et al., 2007 9 34% 155 Varied Varied 9 years (3.1-15.9) Young age; higher dose TBI
Sanders et al., 2008 2 32% 538 Varied FTBI + CY NR (1-30) Age <10 years; Malignancy
23% 108 Varied BU + Chemo
Dvorak et al., 2008 10 8% 25 Varied Varied 6.5 years (1-15) Only seen in FTBI recipients
Bailey et al., 2008 3 52% 33 Mainly malignancy FTBI + Chemo 4 years (0.5-8.5) Unrelated donors
Sanders et al., 2011 11 12% 137 SAA only CY / CY + TBI 21.8 years (1-38.1) TBI
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; PID, primary immunodeficiency; FTBI, fractionated total-body
irradiation; NR, not reported; F/U, follow-up; CR1, first complete remission.
*Studies including only unfractionated TBI were excluded.
1726 Biol Blood Marrow Transplant 17:1725-1738, 2011C. C. Dvorak et al.prepubertal and still growing, are a unique population
in which the data regarding sequelae in adults after
HCT are not directly relevant. Therefore, endocrino-
logic late effects in children after HCT is an important
field of research to both better understand the
epidemiology and risk factors for the development of
a particular endocrine dysfunction, but also to begin
to develop strategies by which the incidence of these
late effects can be minimized.THYROID DYSFUNCTION (TD)
TD is a commonly encountered problem follow-
ing HCT. TD can be screened for with serum free
T4 (FT4) and thyroid-stimulating hormone (TSH)
levels. There are several distinct patterns of TD,
including overt hypothyroidism (low FT4), subclinical
compensated hypothyroidism (high TSH with normal
FT4), hyperthyroidism (high FT4), and rare classic
autoantibody-mediated thyroiditis.
Current State of Knowledge
Centers have reported incidences of TD in
pediatric patients undergoing HCT between 0% to
52%, depending upon the size of the cohort and the
type of transplants performed (Table 1), with the
larger series generally confirming a 30% incidence
[2-11]. Of note, this is much higher than generally
reported for adult patients, where rates are generally
around 15% for patients receiving fractionated
total-body irradiation (TBI), and even lower for
chemotherapy-based preparative regimens [12].
Because a major risk factor for the development of
TD post-HCT is undergoing HCT before the age of
10 years [2,4,8], this suggests that the developing
thyroid gland may be more susceptible to damage.
The group of children with the highest risk of TD
were those patients undergoing HCT for treatment
of Hodgkin lymphoma, with a very high cumulative
incidence of 73% [2].In general, radiation-based preparative regimens
have been shown to be 1 of the most significant risk
factors for the development of TD [12]. Of note,
fractionated TBI in combination with cyclophospha-
mide (CY) is not significantly more likely to cause
thyroid dysfunction than busulfan (BU) in combina-
tion with CY or other alkylating agents. Because CY
on its own as part of the preparative regimen for the
transplant of patients with severe aplastic anemia
(SAA) only induced a 7% incidence of thyroid dysfunc-
tion [2], it appears that the administration of BU may
also be a significant risk factor, although other reports
have challenged this [5-7].
Gaps in Current Knowledge
It remains to be determined if reduced-toxicity
regimens incorporating BU in combination with the
nonalkylating fludarabine produce a lower risk of
TD than seen with classic BU plus CY regimens.
In children with SAA, single-agent graft-versus-
host disease (GVHD) prophylaxis was associated
with extremely high rates of hypothyroidism 5 years
post-HCT (82%) compared with those receiving
3-drug GVHD prophylaxis (16%) [13]. Also, children
undergoing unrelated donor HCT are more likely to
develop hypothyroidism than those receiving trans-
plants from matched siblings (36% versus 9%) [3].
This suggests that a subclinical GVHD-like phenom-
enamay play a role in the development of some cases of
thyroid dysfunction following allogeneic HCT [7,14].
Recommendations for Future Research
The majority of TD seen post-HCT is primary
hypothyroidism, with central hypothyroidism being
less common [2,3]. Therefore, local damage, especially
from TBI, appears to be a common causal agent.
To the best of our knowledge, an attempt to shield
the thyroid during TBI has never been reported.
However, this approach has been successfully applied
to the gonads, thymus, eyes, and lungs [15-18].
Table 2. Studies of Growth Impairment following Pediatric HCT*
Reference
Incidence of Growth
Impairment Number Disease Conditioning F/U Median (Range) Risk Factors
Huma et al., 1995 21 20% 72 Leukemia FTBI + Chemo 7.1 years (1.2-12.9) CI, HCT for ALL
Giorgiani et al., 1995 22 54% 37 Varied FTBI + Chemo >2 years (NR) Prior CI
9% 22 Varied BU + Chemo
Cohen et al., 1996 23 82% 28 Varied Varied 7.9 years (3.2-11.4) TBI, CI
Sanders et al., 2005 24 84% 107 Varied FTBI + CY + CI 11 years (2.7-23) CI, HCT for ALL
Leung et al., 2007 9 39% 155 Varied Varied 9 years (3.1-15.9) Young age; higher dose TBI
Dvorak et al., 2008 10 24% 24 Varied Varied 6.5 years (1-15) Only seen in FTBI recipients
FTBI indicates fractionated total-body irradiation; CI, cranial irradiation; NR, not reported.
*Studies including unfractionated TBI were excluded.
Biol Blood Marrow Transplant 17:1725-1738, 2011 1727Endocrine Dysfunction after HCT in ChildrenObviously this approach would be easiest to implement
in the rare patients receiving TBI for the treatment of
a nonmalignant condition. In patients with leukemia,
care would need to be taken to ensure that the marrow
cavities in the vicinity of the thyroid were properly
treated, although actual recurrence of leukemia in the
thyroid gland itself appears to be vanishingly rare [19].
Another possibility would be to provide physiologic
TSH-suppressive doses of exogenous thyroxine, in
order to induce a metabolic quiescence in the thyroid
gland. A small pilot trial in 14 patients undergoing
irradiation for Hodgkin’s lymphoma suggests that this
method may be effective [20], and it would potentially
be translatable to patients undergoing TBI. However,
the delayed nature ofTDpost-HCTdoes present a sig-
nificant barrier to adequately measuring the effect of an
intervention, and TD is 1 of the easiest late effects to
monitor for and manage, making prevention of TD
a relatively lower priority topic to study.GROWTH IMPAIRMENT
Problems obtaining final predicted adult height are
a post-HCT complication unique to the pediatric
population. Although pituitary production of growth
hormone (GH) plays an important role in determining
final height, many other factors play a role, including
nutritional status, thyroid function, corticosteroid
therapy, and the production of sex hormones during
the pubertal growth spurt. One mechanism by which
GH functions is via the stimulation of production of
both insulin-like growth factor-1 (IGF-1) and
IGF-binding protein-3, a carrier molecule that
enhances the plasma half-life of IGF-1. In patients
with decreased linear growth, measurement of serum
levels of these 2 molecules is thus an easy method to
screen for true decreased production of GH, as
opposed to other etiologies for growth impairment.Current State of Knowledge
There are major difficulties in interpreting the
literature on growth impairment following pediatric
HCTbecause of differences in howgrowth impairmentis defined.As seen inTable 2, the exact incidence of gas-
trointestinal post-HCT varies widely between reports,
likely because of differences in the age of the patients
at the time of HCT, the type of preparative regimen
utilized, and the inclusion of patients who did or did
not receive additional cranial irradiation. Nevertheless,
the reports demonstrate incidences ranging from 20%
to 85% [9,21-24].
Clearly, irradiation-based conditioning regimens
play the largest role in the development of growth
impairment post-HCT [5,9]. However, the exact role
of BU or other alkylators in the development of
growth impairment is less clear. Several groups have
reported low rates of growth impairment with
BU-based regimens [5,6,22,25], unless they also
received cranial irradiation. In patients with genetic
diseases undergoing HCT, growth is usually not
affected by BU-based preparative regimens [26], unless
the HCT is performed during the adolescent growth
spurt [27]; HCT may actually accelerate growth in
patients where the underlying disease (such as thalasse-
mia) was inhibiting it [28].
Similar to TD, age\10 years at the time of HCT
is associated with the highest risk of growth impair-
ment [24,25]. Fortunately, younger patients also
show the best response to GH administration [24].Gaps in Current Knowledge
It is still unknown what the impact of GH
deficiency is on aspects of metabolism unrelated to
linear growth, such as muscle and lean body mass.
Similarly, we do not yet understand what happens to
GH-deficient patients who are treated with recombi-
nant GH during adolescence, but then discontinue
GH replacement once epiphyseal fusion occurs and
final adult height is obtained. Another major gap in
current knowledge regarding growth impairment is
what the impact of non-TBI-based conditioning
regimens, especially newer reduced-intensity and
nonmyeloablative regimens. It is possible that as we
move away from TBI-containing regimens growth
impairment because of biochemical GH deficiency
following HCT may become a thing of the past, or
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1728 Biol Blood Marrow Transplant 17:1725-1738, 2011C. C. Dvorak et al.only occur rarely such as in patients who have signifi-
cant pre-HCT radiation exposures.Recommendations for Future Research
Because irradiation likely plays the largest role in
the development of this late effect, given the practical
difficulties of shielding the pituitary gland the easiest
step will be the development of preparative regimens
that avoid the use of full-dose TBI or preferably even
no TBI, while still providing optimal engraftment
and protection from malignant relapse.BONE HEALTH: LOW BONE MINERAL
DENSITY (BMD)
Current State of Knowledge
Only 7 studies have been published that address
bone loss in pediatric HCT recipients (Table 3).
Only 1 of these studies was prospective [29]; the
remainder were cross-sectional, and most of them
were limited by small sample size (10-66 participants)
[30-35]. BMD was determined by a dual-energy X-ray
absorptiometry scan in most studies [33]. A mild
reduction in mean BMD Z-score (either total body
or lumbar) was observed (mean about 21.0, range:
25.2 to 12.3). A significant proportion of pediatric
HCT recipients transplanted between 0.6 and 18 years
of age had a Z-score between21 and 22 (18%-33%),
and even below 22 (6%-21%).
The pathogenesis of bone loss after HCT is multi-
factorial. Some of the risk factors are general (gender,
age, physical inactivity, poor nutritional status, inade-
quate intake of calcium and/or vitamin D, Caucasian
or Asian race, family history), and some are specific to
cancer treatment and/or HCT (chemotherapy, TBI/
craniospinal irradiation, the malignancy itself, cortico-
steroids, cyclosporine, granulocyte-colony stimulating
factor, endocrine deficiencies, including growth
hormone deficiency and hypogonadism, GVHD or
its treatment, direct effects of conditioning regimens
on bone marrow stromal cells, cytokine release after
HCT, and reduced production of growth factors)
[36-46]. Notably, however, many of the purported
risk factors are only presumed as such based on their
mode of action and effects on bone formation and/or
resorption in various diseases, animal models, or
in vitro experiments.
Only 1 prospective study in children has been
published that longitudinally assessed changes in
BMD before and after HCT [29]. Most significant
bone loss occurred within the first 6 months after
transplantation. The number of patients with aZ-score
below 21 increased from 34% at baseline to 52% 1
year after HCT. Several prospective studies in adult
HCT recipients have demonstrated that a decrease
Biol Blood Marrow Transplant 17:1725-1738, 2011 1729Endocrine Dysfunction after HCT in Childrenin BMD is preceded by changes in the markers of bone
turnover. A consistent finding in adult HCT is a de-
crease in bone formation and an increase in bone
resorption.
There is insufficient data in pediatric HCT recip-
ients to determine whether similar changes in bone
turnover occur in children. Based on 1 prospective
study, which examined the levels of serum bone
specific alkaline phosphatase, osteocalcin, and urinary
N-telopeptide before and up to 12 months after HCT
[29], it appears that bone formation in children may be
similarly reduced.
The mechanisms through which changes in bone
turnover are evoked by the various risk factors have
been previously reviewed [36,40,47]. Of particular
relevance to HCT recipients are direct effects of
myeloablative regimens and the acute release of
cytokines on osteoblastic and osteoclastic activity
after HCT. Myeloablative therapy can directly
damage the recipient’s osteoprogenitor cells within
the bone marrow stroma independently of secondary
effects on gonadal function and GH secretion,
negatively affecting bone formation [41,48,49].
Moreover, a marked ‘‘cytokine storm’’ (interleukin
[IL]-6, IL-7, granulocyte-colony stimulating factor,
macrophase-colony stimulating factor, tumor necorsis
factor-a) occurs within the first 3 weeks after HCT,
which stimulates osteoclasts and increases bone
resorption [43,47,48,50,51]. The main mediator of
these pro-resorptive effects on bone is thought to be
the RANK/RANKL/OPG pathway [52,53]. Receptor
activator of the nuclear factor-kB ligand (RANKL)
and RANKL/OPG (osteoprotegerin) ratio increase
after HCT, reaching a peak at 3 weeks, stimulating
osteoclastogenesis [48,54]. It is currently unknown
whether similar changes occur in children after HCT
and whether OPG, a decoy receptor that competes
with RANKL, can counterbalance these effects.
Some of these biomarkers could be used as predic-
tors of bone recovery. In children, the osteocalcin level
at 100 days after HCT predicted recovery from the
initial bone loss by 1 year [29]. In adult HCT recipi-
ents, lower IGF-1 levels and higher cytokine levels
after HCT correlated with lower BMD at 1 year
[43,48,54].
Studies in adult HCT recipients have shown
that BMD can improve years after HCT [39,47,55].
Because peak bone mineral accretion occurs during
adolescence and young adulthood, children who
undergo HCT at a very young age would presumably
still have time to regain BMD. Data to support this
presumption is limited. Some studies have shown that
the potential for stromal reconstitution after HCT
may be greater young children [34], especially those
younger than 5 years compared with older than 8 years
[49]. However, Bhatia et al. [30] found a positive
correlation between age at HCT and BMD. Thus, itremains to be determined whether there is an age effect
and how it affects BMD outcome.
Gaps in Current Knowledge
The limitations of the current studies in pediatric
HCT recipients are severalfold. The first is that the
majority of the studies have small sample sizes and
are cross-sectional. Furthermore, it is unclear whether
there are age-related differences in predisposition to
bone loss and/or subsequent BMD recovery after
HCT. In addition, markers of bone turnover have
been insufficiently studied to determine if bone resorp-
tion is increased after HCT and there is a potential for
identifying biomarkers that would help identify pa-
tients at risk who would require closer follow-up and
an appropriate intervention to prevent or reverse
bone loss.
Recommendations for Future Research
Prospective controlled studies are needed to define
the time course of changes in bone turnover and BMD
before and following HCT, incidence and severity of
bone loss, and whether age at HCT is a factor in
BMD recovery. By identifying risk factors, these stud-
ies should better define a population at risk. Future
studies should also have multiple biologic aims: to
identify the prevalence and the degree of vitamin D
deficiency (which may be a significant contributor in
certain geographic regions), to define biological
predictors of BMD recovery, and to decide which
markers of bone formation and resorption are most
informative in children. Finally, we need to identify
the time period and suitable mode of intervention to
provide patients with weight-bearing exercise after
HCT, as this intervention has been clearly shown to
improve BMD.BONE HEALTH: OSTEONECROSIS
Current State of Knowledge
Osteonecrosis (ON) was first recognized as
a complication of HCT in 1987 [56]. Only a few
papers have addressed the occurrence of ON in
pediatric HCT recipients where the prevalence ranges
from 1.3% to 14% [9,57-59], with even higher
occurrence (44%) being found in pediatric allogeneic
HCT recipients who underwent routine screening
for ON by magnetic resonance imaging (MRI) [33].
The true prevalence, however, is unknown as it can
only be determined by prospective screening with
MR, which is a much more sensitive method of
detection of ON than plain radiographs [12,58,60-62].
In children, knees (31%-40%) are the most
frequent site of ON, followed by hips (19%-24%),
shoulders (9%), and other sites [33,63-65]. The
Figure 1. Pathophysiology of AVN after HCT.
1730 Biol Blood Marrow Transplant 17:1725-1738, 2011C. C. Dvorak et al.majority of patients manifest ON in 2 or more joints
[12,59,63,65]. Typically, ON occurs within 3 years
after HCT, the earliest time point being 1 to 6
months after the onset of steroid therapy, particularly
if MRI is used for detection [45,59,62,63,65-68].
A median interval for the development of ON is
11 months after HCT in children [57].
Patients usually present with either vague, diffuse
bone pain, presumably because of increased intraoss-
eous pressure, or joint-related pain because of an
effusion. Hip involvement is typically manifested
by groin pain. Once subchondral collapse and
articular deformity occur, arthritic-type joint pain
predominates accompanied by functional limitation
(limp, reduced range of motion) [66,69]. However,
during early stages of ON, patients may have mild
transient bone pain during treatment or they
may be completely asymptomatic and not necessarily
progress to symptomatic disease [33,62]. If left
untreated, joint destruction usually occurs within
1 to 5 years after the onset of symptoms [66,70].
Once disease progresses beyond a certain point,
collapse of necrotic bone is inevitable. The reparative
processes are usually ineffective, and actually counter-
productive, leading to further separation of acellular
necrotic bone tissue from viable tissue by a fibrous
layer, preventing revascularization [68,69,71]. The
risk of subchondral fracture of the necrotic bone
leading to joint collapse is determined by the size
(best assessed using the necrotic arc index) and
location of the necrotic lesion [72]. For example, in-
volvement of\10% to 15% of the femoral head and
less than a third of the weight-bearing portion carries
a good prognosis, whereas involvement of .25% of
the femoral head or more than two-thirds of the
weight-bearing portion carries a poor prognosis
[68,69,73].
The pathogenesis of ON is multifactorial. Several
mechanisms have been proposed, including increasedintraosseous pressure or intraluminal obliteration
that compromise intramedullary blood flow, leading
to marrow ischemia, and ultimately necrosis [65]
(Figure 1). The likely contributing mechanisms are
defective bone repair because of damage to the bone
marrow stroma, immunosuppression, as well as radia-
tion and drug induced injury to the vessel wall and
vasculitis [59,66,68,69,71,74-77].
There are multiple risk factors for the develop-
ment of ON that occur in pediatric HCT recipients
at a median age of 14.4 years [57]. Higher incidence
of ON has been reported in patients exposed to
TBI-based conditioning regimens [57,59,78],
presumably because of radiation-induced microvascu-
lar damage [79], in adult patients with acute leukemia
and aplastic anemia compared with acute myelogenous
leukimia, chronic myeloid leukemia, and other
diagnoses [59], and in recipients of allogeneic HCT
(particularly unrelated) compared with autologous
HCT [66,74,78]. The latter likely explains an
increase in risk in patients transplanted after
1985 when unrelated donor HCTs became more
common and newer immunosuppressive agents were
introduced [74]. The data about the association
between gender and the incidence of ON have been
inconsistent. Although GVHD, both acute and
chronic, has been associated with ON, it is unclear
whether it plays an independent pathogenic role
because it is strongly correlated with the use of steroids
[57-59,66,74,80]. An argument for an additional
independent role of GVHD is that it increases the
risk for microangiopathy [81-83]. Corticosteroids are
the strongest risk factor for ON, with both the
cumulative dose and duration of treatment playing
a role [57,58,65,66,77,78,84-86]. Several mechanisms
for this effect have been proposed, including
altered lipid metabolism, adipocyte hypertrophy,
stimulation of adipogenic differentiation of bone
marrow stem cells at the expense of osteogenic
Biol Blood Marrow Transplant 17:1725-1738, 2011 1731Endocrine Dysfunction after HCT in Childrendifferentiation, leading to the formation of fat emboli
and fatty infiltration of the bone marrow, or a direct
effect on osteocyte apoptosis [67,68]. The risk of
ON increases with the number of drugs used
for immunosuppression, including prednisone,
cyclosporine, tacrolimus, and mycophenolate mofetil
[74,78], because of their thrombogenic effects, as
well as through vascular damage and dyslipidemia
[87-90].
An association between low BMD and ON has not
been characterized beyond the observation that both
can coexist in pediatric HCT patients [65]. Although
the causative link is absent, it is conceivable that higher
BMDwould likely improve the biomechanical proper-
ties of the bone, and perhaps delay the collapse of the
necrotic bone. There is a significant overlap between
the risk factors for low BMD and ON. In addition,
the 2 conditions may share pathogenic pathways, and
therefore have additive effects. For example, impaired
osteoblast activity contributes to reduced BMD in
both pediatric HCT and adult HCT patients
[29,43,48,91-93]. Reduced number of osteoblast
precursors may, in turn, adversely affect the re-
generative potential of the osteogenic compartment
and the course of ON [66,77,94,95].
Gaps in Current Knowledge
The major limitation of current studies in pediat-
rics is the lack of an animal model, an insufficient
number of patients to allow identification of patients
at high risk for progression of ON, and inadequate
assessment of asymptomatic disease. Furthermore,
there is no consensus regarding optimal screening
and treatment of early-stage ON. Clearly, MRI is the
most sensitive screening modality; however, its cost
effectiveness, especially in view of the lack of a reliably
effective intervention in early-stage disease, remains an
obstacle.
Recommendations for Future Research
Prospective studies with screening MRIs are
needed to identify the incidence of ON after pediatric
HCT, the natural history of asymptomatic ON
detected byMRI, and appropriate preventive interven-
tions. Given the significant prevalence of ON in
non-HCT acute lymphoblastic leukemia patients, as
part of a prospective study, a baseline MRI would
need to be performed on all patients before HCT.
Only then will progress be made in discerning the
effectiveness and safety of pharmacologic interven-
tions in preventing post-HCT ON.REPRODUCTIVE RISKS
The reproductive risks of HCT include gonadal
failure, infertility, and pubertal failure.Current State of Knowledge
Postpubertal individuals
Females: The ovary is particularly sensitive to the
adverse effects of cancer treatments because of the
finite number of germ cells present in the postnatal
ovary [96,97]. Because reproductive life span is
determined by the size of the follicular pool,
cancer treatments that cause follicular depletion
accelerate the onset of menopause [98]. The irrevers-
ible gonadotoxic effects of some chemotherapeutic
agents are well documented, particularly for alkylating
agents such as CY [99,100]. In women 30 to 39 years
of age, a dose of 9 gm/m2 of CY results in ovarian
failure, while in women who are a decade younger,
20 gm/m2 causes a similar effect. In contrast, the
prepubescent female has been shown to tolerate as
much as 25 to 30 gm/m2 of CY and still retain
ovarian function [101].
Ovarian failure after HCT has been observed in
65% to 84% of pediatric transplant recipients
(Table 4) (165-170). Exposure to CY, BU, and TBI
are associated with gonadal failure, whereas younger
age at transplant is associated preservation ofmenstrual
function [102,103]. It is important to recognize that
studies assessing fertility after HCT are limited by
the fact that they have not accounted for whether
patients were actually trying to conceive. One of the
most comprehensive studies of pregnancy in pediatric
and adult HSC survivors reported that 32 of 708
(4.5%) of postpubertal females became pregnant after
HCT [104]. Pregnancies were most likely to be re-
ported in patients who had been exposed to CY only
conditioning regimens (56 of 103, 54% reported preg-
nancy), compared with BU/CY (0 of 73, 0% reported
pregnancy) or TBI (7 of 532, 1.3%). In general, studies
indicate that fertility is most likely to be preserved in
patients who undergo transplant as young adults
(15-30 years) and receive non-TBI-based conditioning
regimens. Most pregnancies occur 5 to 10 years post-
transplant. Nonetheless, pregnancy has been reported
in patientswho received high dose alkylator-based con-
ditioning andTBI, and even in patients who underwent
more than 1 transplant.
Males: Unlike the female, germ cells in the testes
normally continue toproduce spermduring adulthood.
However, conditioning therapies such as CY and TBI
destroy germ cells within the testes leading to low or
absent sperm production which can subsequently lead
to infertility [105]. Impairment of spermatogenesis
may be permanent or temporary following chemother-
apy [105,106]. The chance of recovery of
spermatogenesis following cytotoxic therapy and the
extent and speed of recovery are related to the agent
used and the dose received. Azoospermia develops in
the majority of postpubertal males exposed to over of
300 mg/kg of cyclophosphamide [105]. Moreover,
Table 4. Studies of Fertility following HCT
Reference Type of Study Number of Patients Summary of Findings
Sanders et al., 1996 104 Retrospective 1326 15.5% of females had ovarian function and 4.5% conceived
Cohort (708 females, 618 males) 24.4% of males had testicular function and 5.7% of partners conceived
79% of pregnancies resulted in a live birth
Females had an increased risk of PTD and LBW infants
Salooja et al., 2001 132 Retrospective 37,362 (all females) 0.6% HCT recipients or female partners conceived
Cohort 87% of pregnancies resulted in a live birth
Female HCT recipients had an increased risk of PTD, LBW,
and Cesarian deliveries
Carter et al., 2006 131 Retrospective 619 5.5% HCT recipients or female partners conceived
Cohort (292 females, 327 males) 85% of pregnancies resulted in a live birth
>2 years post-HCT Risk of miscarriage and stillbirth was no different that sibling controls
Compared with sibling controls Older age, female sex, exposure to TBI 5 less conception
Loren et al., 2011 133 Case Series 178 HCT Fertility is most likely to be preserved in patients: undergo HCTas young
adults (15-30 years) receive non-TBI conditioning regimens males(83 females, 95 males)
PTD indicates preterm deliveries; LBW, low birth weight.
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and low doses (.2-3 Gy) can cause significant
impairment in function. Many (48%-85%) males
who undergo HCT will experience testicular failure
with azoospermia [104,105,107]. Similar to females,
the risk of gonadal failure appears to be dependent on
the type of therapy and the doses administered.
Fertility data in the transplant population are
limited and summarized in Table 4. A large study
of HCT survivors found that 32 of 618 postpubertal
males fathered a child. Pregnancies were most likely
to be reported in patients who had been exposed
to CY only conditioning regimens (26 of 109, 24%
reported pregnancy), compared with BU/CY (3 of
46, 6.5% reported pregnancy) or TBI (6 of 463,
1.3%) [104].
Prepubertal individuals: Normal pubertal develop-
ment requires a functioning hypothalamic-pituitary-
gonadal axis. HCT can result in pubertal delay or
failure in both sexes. Incomplete pubertal develop-
ment or pubertal failure has been reported to occur
in approximately 57% of prepubescent females follow-
ing HCT [2]. However, the risk of delayed puberty is
dependent on the conditioning regimen administered
(16% after 200 mg/kg CY alone, 72% after 16 mg/kg
BU plus 120-200 mg/kg CY, 71% after 10 Gy
single-exposure TBI, 57% after 12-15.75 Gy TBI)
[11,108]. In males, incomplete pubertal development
or pubertal failure has been reported to occur in
approximately 53% of prepubescent males exposed
to HCT [109]. Similar to females, the risk of delayed
puberty is dependent on the conditioning regimen
administered (14% after 200 mg/kg CY alone, 48%
after 16 mg/kg BU plus 120-200 mg/kg CY, 81% after
10 Gy single-exposure TBI, 58% after 12-15.75 Gy
TBI) [11,108]. Boys who receive high dose (.24 Gy)
testicular irradiation for testicular relapse have
a very high risk of pubertal failure requiring
testosterone replacement to develop secondary sexual
characteristics [109].Fertility preservation in females
The ability to lead full reproductive lives is very im-
portant to both female and male HCT survivors.
Indeed, there is evidence that HCT survivors have
persistently elevated concerns about their fertility
even 10 years after treatment [110]. Therefore, there
has been increasing interest in methods to expand the
reproductive options for patients facing fertility-
threatening treatments. Although embryo cryopreser-
vation remains the standard option for adult females
with a committed sexual partner, oocyte cryopreserva-
tion and ovarian tissue cryopreservation (OTC)
technologies have become clinically available experi-
mental options for femaleswithout a partner.These fer-
tility preservation technologies have gained traction,
particularly after the publication of the ASCO fertility
preservation recommendations in 2006 [111]. How-
ever, embryo and oocyte cryopreservation are limited
by the need for ovarian stimulation and oocyte retrieval,
which can delay treatment 2 to 4 weeks. This delay in
treatment is usually not an option for patients with leu-
kemia, who tend to be quite ill with impaired blood
counts at initial presentation. OTC eliminates the
need for ovarian stimulation and does not require
a sperm source. Although investigational, live births
have been reported followingOTCand transplantation
in cancer patients [112]. Currently, this is the only
method available for fertility preservation in prepuber-
tal girls [113-116]. There is a significant concern
regarding the potential for reseeding tumor cells
following ovarian transplantation procedures in
cancers that involve the ovary, such as leukemia. A
recent study of 18 patients with leukemia (chronic
myeloid leukemia or acute lymphoblastic leukemia)
showed that leukemic tumors occurred (4 of 18 cases)
after thawed human ovarian cortical tissue was
xenografted intomice [117].Therefore, transplantation
of ovarian tissue is not recommended in patients with
a history of leukemia. In order to achieve pregnancy
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ture and fertilize oocytes from ovarian tissue in vitro
for embryo transfer. This has only been possible in
the mouse and ongoing studies are being conducted
to move this technology forward [118].
Ovarian suppression
The observation that cancer therapies were less
gonadotoxic in prepubertal girls led to speculation
that ovarian suppression in postpubertal females might
reduce the negative impact of cancer therapies on the
ovary. Ovarian suppression with GNRH analogs ad-
ministered during chemotherapy is the most common
method of ovarian suppression employed. Several
small short-term studies comparing GNRHa plus che-
motherapy to chemotherapy alone have demonstrated
that menstrual function is more likely to be preserved
in women who receive GNRHa during treatment
[119-121]. However, there are insufficient data to
support the use of GNRH agonists in transplant
recipients for the purpose of fertility preservation
[121]. Nonetheless, GNRH analogs have been shown
to reduce menstrual bleeding during cancer therapy
and may be useful for that purpose in the HCT
population [122].
Fertility preservation in males
Sperm cryopreservation remains the best option
for fertility preservation in adolescent and adult males
diagnosed with cancer. All adolescents and young
adults facing cancer therapy should be offered sperm
cryopreservation as a way to preserve future fertility
[123]. Ideally, multiple samples should by cryopre-
served before cancer treatment has begun. In situations
where self-stimulation is unsuccessful, vibratory stim-
ulation, electroejaculation, or surgical sperm extrac-
tion may be used to obtain sperm [124-127]. Even
though sperm banking is a relatively simple process,
there is evidence that oncologists do not routinely
discuss this option with their patients [128]. Fertility
preservation in prepubertal boys remains problematic
and is an active area of investigation. Extracting and
cryopreserving spermatogonial stem cells from boys
in order to later autograft or to mature sperm
in vitro are promising avenues of investigation. Al-
though transplantation of cryopreserved testicular tis-
sue has been successful in mice and rats, data in
humans are lacking [129,130].
Pregnancy outcomes
Overall, pregnancy outcomes appear to be reassur-
ing in survivors of HCT [104,131-133]. Most
pregnancies reported by HCT survivors and their
partners result in a live birth. However, in female
HCT survivors who were exposed to TBI, there
appears to be an increased risk of preterm delivery
and delivery of low birth weight infants. This isconsistent with literature in childhood cancer
survivors and is thought to be related to radiation-
induced structural changes in the uterus [134,135].
In addition, female HCT survivors are at higher risk
of Cesarean section compared with the normal
population (42% versus 16%). This observation may
be related to the perception that transplant survivors
are higher risk and therefore pregnancies are
managed differently than the general population.
Although pregnancy outcomes of male survivors
of HCT have been reported to be reassuring overall,
1 study of childhood cancer survivors reported
that the likelihood of having a live birth was lower
among survivors compared with siblings (relative
risk 5 0.77, P 5 .007) [136]. Nonetheless, offspring
of male and female HCT recipients do not appear to
be at increased risk for birth defects, developmental
delay, or cancer [132].
Gaps in Current Knowledge
Although data from retrospective cohort studies
exist estimating the risk of pubertal problems and
gonadal failure after HSC, there are no accurate
estimates of fertility in this population. It must be rec-
ognized that retrospective reports of pregnancy after
HCT are limited by ascertainment bias and do not
determine whether patients have actually tried to
conceive and have experienced difficulty, or whether
HCT survivors simply are less likely to attempt preg-
nancy. Moreover, there are limited data assessing the
reproductive risk of newer conditioning regimens
before HCT. Although lower intensity conditioning
regimens without exposure to CY and TBI appear to
be less deleterious to reproductive function, more
research is needed to determine which regimens are
least gonadotoxic but equally effective for treatment.
Such information would be useful in order to
adequately counsel patients regarding their reproduc-
tive horizon and target fertility preservation technolo-
gies to those at highest risk.
After HCT, some females will resume menstrual
function. Although measures of ovarian reserve are
likely to be impaired post treatment, it is not clear
whether these measures predict fertility and age at
menopause in cancer survivors. Understanding the
significance of measures of ovarian reserve would
greatly improve counseling about fertility, contracep-
tion, and long-term ovarian function post-HCT.
There are also significant gaps in knowledge in the
areas of contraception and hormone replacement ther-
apy after HCT. Although the risk profile of hormonal
contraceptives may be less favorable in HCT survivors
with concomitant medical problems compared with
the general population, the safety and efficacy of con-
traception has not been studied in this population.
Moreover, in female HCT survivors with premature
ovarian failure, the optimal regimen for hormone
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term benefits and risks to the reproductive system of
various regimens used for HCT are lacking.
Recommendations for Future Research
As outlined above, major gaps in knowledge
regarding the reproductive risks, fertility preservation
options, and long-term contraceptive and endocrine
needs of the HSC population exist. Therefore, there
is an urgent need to conduct research in various aspects
of reproductive health in the transplant population.
Large prospective cohort studies assessing clinically
meaningful reproductive outcomes in HCT recipients
receiving newer preparative regimens are needed to
better define the reproductive risks associated with
these therapies. Furthermore, more data are needed
to determine whether ovarian suppression during
HCT decreases risk of reproductive and/or gonadal
failure.
Additional research is necessary to determine
whether measures of ovarian reserve predict fertility
and time tomenopause inmenstruating transplant sur-
vivors. This would greatly improve post treatment
counseling regarding fertility, contraception, and an-
ticipated timing of menopause. Studies assessing the
safety and efficacy of contraceptives and hormone
replacement regimens may transform care and could
have a major impact on the long health and quality
of life of HCT recipients.CONCLUSIONS
The developing child is significantly more likely to
be affected by endocrinopathies or poor bone health
than a fully mature adult; therefore, the need for
research and interventions in this unique patient pop-
ulation is significant. A large prospective trial that
evaluates pre-HCT endocrine function and then
follows the same tests on a routine basis post-HCT
would significantly add to our current knowledge
and assist in defining interventions.
Although thyroid dysfunction and growth impair-
ment can be managed with replacement hormones,
this damage can be permanent and result in life-long
need for medications. Similarly, low BMDor avascular
necrosis following HCT can lead to significant
long-term problems with ambulation and quality of
life. Finally, for many parents of young children being
considered for HCT, the thought that their child may
be sterile can be emotionally devastating and may
prohibit them from proceeding with HCT. Advances
that could minimize this risk would likely increase
the acceptance of HCT as a therapeutic alternative,
particularly for some nonmalignant conditions.
Thus, in order to maximize both access to HCT and
the quality of life post-HCT for our pediatric patients,further research is urgently needed in the field of
endocrinopathies, bone health, and fertility.ACKNOWLEDGMENTS
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